SOPHiA GENETICS SA Business Summary

SOPHiA GENETICS SA (SOPH) operates a cloud-native Software-as-a-Service (SaaS) model centered on its proprietary SOPHiA DDM™ platform, which leverages artificial intelligence to analyze complex genomic and multimodal data. The company generates revenue primarily through a "land and expand" transactional model, charging healthcare institutions and biopharmaceutical companies per-analysis fees, supplemented by recurring platform access subscriptions and bundled laboratory equipment services. Its operations are divided into two primary segments: Clinical, which provides diagnostic and prognostic insights for oncology and rare diseases, and BioPharma, which supports drug discovery and clinical trial optimization. Within the competitive landscape, SOPHiA GENETICS distinguishes itself through a decentralized data-sharing approach, positioning it as a flexible alternative to centralized competitors like Tempus AI, Flatiron Health, Agilent Technologies, and Illumina Connected Analytics. Founded in 2011 by Dr. Jurgi Camblong, Dr. Pierre Hutter, and Prof. Lars Steinmetz, the company is led by a management team with deep pedigree in life sciences and technology. Dr. Jurgi Camblong, a molecular biologist with a PhD from the University of Geneva, currently serves as CEO, though a succession plan is in place for President Ross Muken—a former healthcare equity research lead at Evercore and CFO of Click Therapeutics—to assume the CEO role in July 2026. The executive suite includes Chief Technology Officer Abhimanyu Verma, who previously spearheaded data science and AI enablement at Novartis and GE, and CFO George Cardoza, a veteran of NeoGenomics and Quest Diagnostics. The company is backed by prominent investors including the aMoon Fund, Hitachi Ventures, and Balderton Capital, with a board of directors featuring industry leaders such as Chairman Troy Cox and former Agilent CFO Didier Hirsch.